A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis
- 21 May 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (8), 1926-1933
- https://doi.org/10.1111/liv.14534
Abstract
Background/Purpose Although ursodeoxycholic acid (UDCA) is a first‐line treatment for primary biliary cholangitis (PBC), 20‐30% of patients with PBC exhibit an incomplete response to UDCA. Recently, the UDCA Response Score was proposed for predicting response to UDCA using pretreatment parameters in patients with PBC. We aimed to validate the UDCA Response Score in Japanese patients with PBC. Methods Registry data of Japanese patients (n=873) were collected. Patients with data on all clinical parameters required for calculating the UDCA Response Score were selected. The endpoint was UDCA response, defined as alkaline phosphatase <1.67 times the upper limit of the normal value after 12 months of UDCA treatment. Results All parameters were available in 804 patients (male/female=120/684, age 58.9 [interquartile range 51.1‐66.9] years). Bezafibrate was commenced within 12 months of UDCA in 78 patients (9.7%) because of the lack of an early response. We found that the endpoint was not reached in these 78 patients, and the area under the receiver operating characteristic curve (AUROC) of the score was 0.74 (95% confidence interval [CI] 0.70‐0.79). The AUROC was 0.77 (95% CI 0.70‐0.83) in patients undergoing UDCA monotherapy (n=726). Finally, the AUROC of the modified UDCA Response Score using only data from the treatment start date was 0.80 (95% CI 0.70‐0.90) in patients receiving a combination therapy of UDCA and bezafibrate (n=160). Conclusion The validity of the UDCA Response Score was acceptable in Japanese patients; this score will be informative in patients treated with a combination therapy of UDCA and bezafibrate.This publication has 17 references indexed in Scilit:
- Primary biliary cholangitis: a comprehensive overviewHepatology International, 2017
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitisJournal of Hepatology, 2017
- Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyGastroenterology, 2015
- Guidelines for the management of primary biliary cirrhosisHepatology Research, 2014
- Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary CirrhosisThe American Journal of Gastroenterology, 2010
- Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2009
- Primary biliary cirrhosisJournal of Hepatology, 2009
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisJournal of Hepatology, 2008
- Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2006
- IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?The Lancet, 1987